We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DarioHealth (DRIO) Moves 12.9% Higher: Will This Strength Last?
Read MoreHide Full Article
DarioHealth Corp. (DRIO - Free Report) shares ended the last trading session 12.9% higher at $7.9. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 16.9% gain over the past four weeks.
DarioHealth scored a strong price increase on investors’ optimism surrounding the securities purchase agreements with current long term Dario institutional investors as well as new fundamental investors for the purchase and sale of 3,454,559 shares of common stock, at a price of $6.80 per share. The closing of the offering is expected to occur on or about July 23, subject to the satisfaction of customary closing conditions. DarioHealth intends to use the net proceeds from the offering for working capital, investments, acquisitions and general corporate purposes.
This company is expected to post quarterly loss of $0.74 per share in its upcoming report, which represents a year-over-year change of +69.2%. Revenues are expected to be $6.19 million, up 15.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For DarioHealth, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on DRIO going forward to see if this recent jump can turn into more strength down the road.
DarioHealth is part of the Zacks Medical - Instruments industry. ClearPoint Neuro, Inc. (CLPT - Free Report) , another stock in the same industry, closed the last trading session 2.5% lower at $15.03. CLPT has returned -16.8% in the past month.
ClearPoint Neuro's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.27. Compared to the company's year-ago EPS, this represents a change of -28.6%. ClearPoint Neuro currently boasts a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
DarioHealth (DRIO) Moves 12.9% Higher: Will This Strength Last?
DarioHealth Corp. (DRIO - Free Report) shares ended the last trading session 12.9% higher at $7.9. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 16.9% gain over the past four weeks.
DarioHealth scored a strong price increase on investors’ optimism surrounding the securities purchase agreements with current long term Dario institutional investors as well as new fundamental investors for the purchase and sale of 3,454,559 shares of common stock, at a price of $6.80 per share. The closing of the offering is expected to occur on or about July 23, subject to the satisfaction of customary closing conditions. DarioHealth intends to use the net proceeds from the offering for working capital, investments, acquisitions and general corporate purposes.
This company is expected to post quarterly loss of $0.74 per share in its upcoming report, which represents a year-over-year change of +69.2%. Revenues are expected to be $6.19 million, up 15.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For DarioHealth, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on DRIO going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
DarioHealth is part of the Zacks Medical - Instruments industry. ClearPoint Neuro, Inc. (CLPT - Free Report) , another stock in the same industry, closed the last trading session 2.5% lower at $15.03. CLPT has returned -16.8% in the past month.
ClearPoint Neuro's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.27. Compared to the company's year-ago EPS, this represents a change of -28.6%. ClearPoint Neuro currently boasts a Zacks Rank of #3 (Hold).